Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for Its Alcohol Substitute Beverage Product
Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for Its Alcohol Substitute Beverage Product
Vancouver, Canada, July 19, 2024 -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced a strategic engagement with JS First Sdn. Bhd ("JS First"). This partnership aims to source global manufacturers and distributors for Clearmind's groundbreaking MEAI-based alcohol substitute beverages, marking a significant step towards international expansion.
加拿大溫哥華,2024年7月19日——Clearmind Medicine Inc.(納斯達克股票代碼:CMND,德國交易所股票代碼:CWY0)("Clearmind" or the "Company"),一家專注於開發新型迷幻藥物導出的治療產品以解決未得到有效治療的健康問題的臨床生物技術公司,宣佈與JS First Sdn. Bhd.("JS First")達成戰略合作。這一合作旨在尋找全球製造商和分銷商,爲Clearmind的顛覆性基於MEAI的無酒精代替飲料尋找市場,是向國際市場擴張的重要一步。
This move follows Clearmind's recent announcement regarding its entry into the non-alcoholic beverage market with its proprietary, neurologically active novel alcohol replacement beverage, which was granted patents in the U.S., India and Europe. The innovative beverage, designed to offer a healthier alternative to traditional alcoholic drinks, is set to revolutionize the industry by providing the same social benefits of alcohol without the associated negative health impacts.
這一舉動是繼Clearmind最近宣佈其專有的、具有神經活性的新型無酒精替代飲料進軍無酒精飲料市場的消息之後,並且已在美國、印度和歐洲獲得專利。這種旨在提供一種健康的替代傳統酒精飲料的革新性飲料,將通過提供與酒精相同的社交福利,而不帶來相關的負面健康影響而改變行業格局。
The engagement aims for JS First to conduct comprehensive research on manufacturing and licensing rights for Clearmind's MEAI-based beverages in foreign markets, identify and secure high-quality manufacturing partners in multiple countries and establish relationships with distributors across the globe, including in the U.S., Europe, Africa and Southeast Asia, for widespread market penetration.
這次合作旨在通過JS First對國外市場上Clearmind的基於MEAI的飲料進行全面的製造和授權研究、確定並確保多個國家的高質量製造夥伴,並與全球的分銷商建立關係,包括美國、歐洲、非洲和東南亞,實現廣泛的市場滲透。
"We are excited to partner with JS First, whose expertise and extensive network in the manufacturing and distribution sectors will be invaluable as we expand our global footprint. This collaboration is a crucial step towards making our novel alcohol replacement beverages available to consumers worldwide," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine Inc.
"我們很高興能與JS First合作,他們在製造和分銷領域的專業知識和廣泛的網絡將在我們擴大全球業務的過程中發揮重要作用。這一合作是實現讓我們的新型無酒精飲料面向全球消費者的關鍵一步",Clearmind Medicine Inc.的首席執行官Adi Zuloff-Shani博士說。
According to a report by IWSR, the leader in global beverage alcohol data and insights, no- and low-alcohol consumption across the world's leading 10 no/low markets, which account for approximately 70% of global no/low-alcohol volumes, grew by +5% in volume in 2023, and the market is now worth over $13 billion. The no/low alcohol category is forecast to grow at a volume CAGR of +6% between 2023 and 2027.
根據全球飲料酒精數據和見解領域的領袖IWSR發佈的報告,全球前十大無酒精/低度酒市場的無酒精/低度酒消費約佔全球無酒精/低度酒總量的70%,2023年其體積增長了+5%,現在市值超過130億美元。無/低度酒類別的銷售量複合增長率預計將在2023年至2027年期間達到+6%。
About Clearmind Medicine Inc.
關於Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Clearmind是一家臨床階段的致幻劑製藥生物技術公司,專注於發現和開發解決廣泛且未被滿足的健康問題,包括酒精使用障礙的新型致幻藥品。其主要目標是研究和開發以致幻劑爲基礎的化合物,並嘗試將其作爲受監管的醫藥品、食品或補充品商業化。公司的知識產權組合目前包括十八個專利族。在必要時,公司擬尋求對其化合物的其他專利,並將對收購其他知識產權保持樂觀。
The Company's intellectual portfolio currently consists of eighteen patent families including 28 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
公司的知識產權組合目前包括18個專利系列,其中28項已獲批准。公司打算在合適的時候申請更多的藥物化合物專利,並將會以機會主義的方式收購更多的知識產權來建立其知識產權組合。
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol "CWY0."
欲了解更多信息,請訪問:
For further information visit: or contact:
要獲取更多信息,請訪問:或聯繫:
Investor Relations
invest@clearmindmedicine.com
投資者關係
電話:(604) 260-1566
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
美國:CMND@crescendo-ir.com
美國:CMND@crescendo-ir.com
General Inquiries
一般查詢
Info@Clearmindmedicine.com
網站的引用和鏈接僅供參考,本新聞稿不會將這些網站的內容納入其中。Clearmind對第三方網站的內容概不負責。
Forward-Looking Statements:
前瞻性聲明:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses expanding its global footprint and making its novel alcohol replacement beverages available to consumers worldwide. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ("SEC"), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
本新聞稿包含"前瞻性語句",涉及到其他證券法和《私人證券訴訟改革法案》的風險因素。"預計","計劃","期望","相信","尋求","估計"和類似的措辭或這些措辭的變化,預示着前瞻性語句。例如,當公司討論拓展其全球市場並讓其創新性無酒精替代飲料面向全球消費者時,它就在使用前瞻性語句。前瞻性語句不是歷史事實,並基於管理層當前的期望、信念和預測,其中許多本質上具有不確定性。這些期望、信念和預測表示出善意。但是,不能保證管理層的期望、信念和預測將實現,實際結果可能與前瞻性語句中所表達的結果有實質性差異。前瞻性語句受到風險和不確定性的影響,這些風險和不確定性可能導致實際績效或結果與前瞻性語句所表示的績效或結果有實質性差異。更詳細關於公司面臨的風險和不確定因素的描述,請參考公司定期提交給證券交易委員會("SEC")的報告,包括但不限於其於2023年10月31日結束的財年提交給SEC的20-F年度報告中所詳細說明的風險。前瞻性語句僅截至發表日期有效。除非適用的證券法規定否則,否則公司不承擔更新前瞻性語句以反映實際結果、後續事件或情況、假設的變化或影響前瞻性信息的其他因素的義務。如果公司更新一個或多個前瞻性語句,不應推斷出公司將以後會對其進行更新或對其他前瞻性語句更新。已提供網站的參考和鏈接,僅供方便參考,該網站上的信息未納入本新聞稿中。Clearmind不對第三方網站的內容負責。
譯文內容由第三人軟體翻譯。